ArticleJournal of cellular and molecular medicine2026
Mutation in MSH5 Causes Primary Ovarian Insufficiency and Successful Therapeutic Intervention by In Vitro Fertilisation.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mutation in MSH5 Causes Primary Ovarian Insufficiency and Successful Therapeutic Intervention by In Vitro Fertilisation.Journal of cellular and molecular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Primary ovarian insufficiency (POI) is a genetically heterogeneous disorder characterised by cessation of menstruation before the age of 40 years with elevated levels of follicle-stimulating hormone. Germline variants in the MSH5 gene cause POI. In this study, we investigated a Han Chinese family with POI. The proband and her two younger sisters are clinically diagnosed with POI. The proband's parents are phenotypically normal. Whole exome sequencing identified a novel homozygous splice-donor site (c.271+1G>A) variant in the first nucleotide of intron 3 of the MSH5 gene in this proband. Sanger sequencing confirmed that both the younger sisters of the proband also harbour the same homozygous variant, while the proband's parents are carrying this variant in a heterozygous state. This variant causes aberrant splicing of MSH5 mRNA followed by the formation of an alternative MSH5 transcript with complete loss of exon 3. Relative expression of mutant MSH5 mRNA is significantly reduced compared to that of the wild-type transcript. Mutant MSH5 impaired DNA homologous recombination repair as well as significantly lowering the clonogenic survival rate of cell clone formation compared with the wild type. In addition, we also found a significantly higher apoptotic rate and lower cell proliferation rate in the mutant than that of the wild type. We performed egg donation-based in vitro fertilisation for this proband, and two healthy baby girls have been successfully delivered. Our present study reports the first splice-site variant in the MSH5 gene in patients with POI. We also report for the first time the successful therapeutic intervention by in vitro fertilisation for patients with MSH5-associated POI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.